Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00056381
Status:
COMPLETED
Last Update Posted:
2008-10-21
First Post:
2003-03-11
Brief Title:
Safety Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase III Study of the Safety Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count neutropenia
Detailed Description:
Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis candidemia and other invasive fungal infections Anidulafungin is an antifungal agent of the echinocandin class which targets the fungal cell wall of yeast and other filamentous fungi
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A8851005 | None | None | None |